Recent Postings to

Worst Pills, Best Pills Newsletter Articles

  View the entire November 2015 issue in PDF format

  • Drug Industry’s Unacceptable Delays in Reporting Adverse Events To the FDA
    (November 2015)
    Worst Pills, Best Pills News editor Dr. Michael Carome discusses disturbing results from a recent study revealing that pharmaceutical companies too often violate the law by failing to promptly report unexpected serious adverse events linked to use of their products. Delays in report¬ing such events undermine a key component of our nation’s system for monitoring the safety of prescription drugs.
  • News Brief for November 2015
    (November 2015)
    In our news brief this month, we report on the Food and Drug Administration's reckless decision to approve flibanserin (ADDYI), the first drug to treat hypo¬active sexual desire disorder in premenopausal women.
  • Insulin Pumps Need More Scrutiny, Say American and European Diabetes Groups
    (November 2015)
    Insulin pumps have been promoted as an important technological advancement in diabetes care. Find out why Public Citizen’s Health Research Group considers these devices too dangerous to use.
  • Update on the Long-Term Treatment Of Chronic Obstructive Pulmonary Disease
    (November 2015)
    In this article, we provide a detailed update of the various drugs available for the long-term management of chronic obstructive pulmonary disease (COPD). Learn which drugs are safest for treating COPD and which ones we have designated as Do Not Use.
  • Drugs That Cause Hearing Problems
    (November 2015)
    For most people with hearing loss, the condition likely is age-related or due to long-term exposure to loud noise. But for some patients, the cause of the problem can be found in the medicine cabinet. Learn about some commonly used medications that can cause hearing disorders.

  View the entire October 2015 issue in PDF format

  • Questions & Answers
    (October 2015)
    In this month's Question and Answers feature, we respond to readers' questions about our June article on injected drugs for age-related macular degeneration.
  • Initial Ruling in Industry Lawsuit Threatens FDA's Regulation Of Drugs
    (October 2015)
    Learn more about a recent federal court decision that threatens to return us to the days of the late 19th and early 20th centuries, when snake-oil salesmen touted "remedies" that were too often ineffective — and sometimes dangerous.
  • Liraglutide (SAXENDA) for Weight Loss
    (October 2015)
    Find out why the recently approved high-dose form of liraglutide, which was originally marketed for treatment of Type 2 diabetes, is not a safe option for managing weight loss
  • Often-Misused Fluoroquinolone Antibiotics Pose Serious Risks
    (October 2015)
    Fluoroquinolones are the biggest-selling and most overprescribed classes of antibiotics in the U.S. Learn why Public Citizen's Health Research Group designates two of the five available fluoroquinolones as Do Not Use and why the other three should be used only in limited circumstances.
  • More Evidence Linking Hormone Therapy To Cardiovascular Harm in Postmenopausal Women
    (October 2015)
    In this article, we discuss the most recent evidence linking the use of hormone replacement therapy in women after menopause to increased risk of heart attacks, strokes and other serious cardiovascular problems.

Additional Information from Public Citizen

Copyright © 2015 Public Citizen's Health Research Group. All rights reserved.